Francesca Merchionne

Lecce, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese.

Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese.

Journal: Annals of hematology
Published: July 19, 2025

Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology.

Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology.

Journal: Frontiers in oncology
Published: May 12, 2025

Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".

Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".

Journal: Leukemia & lymphoma
Published: July 07, 2023

u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.

u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.

Journal: BMC cancer
Published: May 03, 2016

Azacitidine in the front-line treatment of therapy-related myeloid neoplasms: a multicenter case series.

Azacitidine in the front-line treatment of therapy-related myeloid neoplasms: a multicenter case series.

Journal: Anticancer research
Published: January 01, 2015

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis.

Journal: Leukemia research
Published: September 03, 2014

Challenges and opportunities of microRNAs in lymphomas.

Challenges and opportunities of microRNAs in lymphomas.

Journal: Molecules (Basel, Switzerland)
Published: April 29, 2014

Changes in angiogenesis and hypoxia-inducible factor-1α protein expression in relapsed/refractory indolent non-Hodgkin lymphomas.

Changes in angiogenesis and hypoxia-inducible factor-1α protein expression in relapsed/refractory indolent non-Hodgkin lymphomas.

Journal: British journal of haematology
Published: April 30, 2013

Target therapies in pancreatic carcinoma.

Target therapies in pancreatic carcinoma.

Journal: Current medicinal chemistry
Published: March 06, 2013

Targeted strategies in the treatment of primary gastric lymphomas: from rituximab to recent insights into potential new drugs.

Targeted strategies in the treatment of primary gastric lymphomas: from rituximab to recent insights into potential new drugs.

Journal: Current medicinal chemistry
Published: March 05, 2013

New therapies in multiple myeloma.

New therapies in multiple myeloma.

Journal: Clinical and experimental medicine
Published: July 20, 2007
Showing 1-11 of 11

Last Updated: 09/26/2026